CEP-37251

CEP-37251 is a biological drug developed as an osteoprotegerin (OPG) analogue and functions as a RANKL inhibitor. It was designed to inhibit the activity of the receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11. By inhibiting RANKL, CEP-37251 aimed to prevent bone resorption and loss by blocking osteoclast activation. The drug was initially developed by Cephalon and later associated with Teva Pharmaceutical Industries following acquisition. Its primary indication was osteoporosis, particularly in postmenopausal women, but it was also investigated for potential use in bone metastases and considered for colorectal cancer. Clinical development reached Phase 1 before being discontinued due to lack of further advancement[1][2][3][4][5][9].

Other names

OPG analogueOPG variantOPG variant protein